CYP19A1 and gastric cancer: Exemestane, an inhibitor of aromatase enzymatic function, also demonstrated a similar effect on GC cells.[7] Aromatase is a key enzyme that catalyzes the conversion of androstenedione or testosterone to estradiol or estrone, and a high expression of aromatase was associated with poor overall survival in patients with GC.